Second-Line Switch to Dolutegravir for Treatment of HIV Infection

Second-Line Switch to Dolutegravir for Treatment of HIV Infection

In an open-label, multicenter trial in Kenya, HIV-infected patients following a ritonavir-boosted protease inhibitor regimen were assigned to switch to dolutegravir or continue the regimen. The dolutegravir-based regimen was noninferior.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2023-06, Vol.388 (25), p.2349-2359
Hauptverfasser: Ombajo, Loice A., Penner, Jeremy, Nkuranga, Joseph, Mecha, Jared, Mburu, Margaret, Odhiambo, Collins, Ndinya, Florentius, Aksam, Rukia, Njenga, Richard, Wahome, Simon, Muiruri, Peter, Eshiwani, Sheila, Kimani, Maureen, Ngugi, Catherine, Pozniak, Anton
Format: Artikel
Sprache:eng
Schlagworte:
AIDS
Antiretroviral drugs
Antiviral drugs
Drug dosages
Drug resistance
Enrollments
Genotypes
Global Health
HIV
Human immunodeficiency virus
Infectious Disease
Infectious Disease General
Laboratories
Lipids
Mutation
Patients
Pregnancy
Proteinase inhibitors
Regulatory approval
Ritonavir
Viral Infections
Womens health
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In an open-label, multicenter trial in Kenya, HIV-infected patients following a ritonavir-boosted protease inhibitor regimen were assigned to switch to dolutegravir or continue the regimen. The dolutegravir-based regimen was noninferior.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2210005